Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.
FDA clears Genentech’s Columvi for adults with R/R DLBCL
Genentech’s Columvi will become available in the US in summer 2023. Credit: Coolcaesar / commons.wikimedia.org. Roche Group member Genentech has secured approval from the US
June 16, 2023